Curetis Provides Update on Unyvero LRT FDA 510(k) Submission
Curetis Provides Update on Unyvero LRT FDA 510(k) Submission
– Curetis reiterates that it expects FDA to provide decision on clearance of Unyvero LRT in the second half of 2017
Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 24, 2017 – Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today provided an update regarding the ongoing interactive review by the U.S. Food and Drug Administration (FDA) of its 510(k) application for clearance of the Unyvero Platform and Lower Respiratory Tract Infection (LRT) Application Cartridge.
On April 21, 2017, Curetis participated in a Meeting with a team of FDA reviewers, discussing the FDA’s request for additional information communicated to the Company in March 2017. Meeting minutes have been drafted and confirmed by Curetis and FDA as of May 23, 2017.
Based on the outcome of this meeting and further discussions with the reviewers, FDA is moving forward with review of the Unyvero Platform and LRT Application Cartridge for use initially with tracheal aspirate samples. Curetis believes that clearance of the Unyvero System and LRT Cartridge with one of the most relevant sample types initially could give Curetis a time advantage, being the only provider of a diagnostic solution of this kind. Following clearance of Unyvero LRT with tracheal aspirate samples, Curetis plans to submit data for clearance of the LRT Cartridge for bronchial lavage (BAL) sample types. Originally, Curetis filed for both bronchial lavage (BAL) and tracheal aspirate sample types in its De Novo submission. By making the strategic decision to move forward in this phased approach, Curetis aims to pursue the fastest and least risky regulatory pathway. This decision should render unnecessary a possible Advisory Committee Panel meeting that the FDA has brought up for moving forward with aspirate and BAL sample types at the same time.
Curetis plans to continue working closely with the FDA reviewers to identify an appropriate path to develop or augment the BAL data package, which shall be submitted as part of a proposed future label claim expansion following the potential initial clearance of Unyvero LRT for tracheal aspirates.
“In light of our ongoing discussions with the reviewers, we believe that our request to exclude the BAL sample type from the initial label claims provides the most expeditious path forward for Unyvero in the U.S., and we are pleased that the FDA might issue an initial clearance decision for tracheal aspirates. We look forward to continuing to work closely with the FDA through the interactive review while determining the optimal process through which to file a label claim extension following potential clearance,” said Johannes Bacher, Chief Operating Officer of Curetis. “Apart from additional data on the BAL sample type, we are planning to generate data from the interventional use of the Unyvero LRT product in the routine clinical setting once approved, and to further assess its potential impact on antibiotic stewardship. We strongly believe in the unique, paradigm-shifting potential of Unyvero to inform better, more actionable treatment decisions and promote more efficient antibiotic use in critically ill patients.”
The FDA has requested additional data (e.g. stability data of fresh vs. frozen samples, additional contrived sample testing and adding some reproducibility data) that will require Curetis to conduct incremental wet lab testing at the Company’s facilities in Germany. The total number of additional Unyvero LRT Application Cartridge runs is expected to be around 500 to 1,000 (i.e. 5% to 10% of the total number of more than 10,000 cartridges already run for the LRT clinical studies) and will likely be completed in the coming 3 to 4 months.
“We are working diligently to provide this additional information to the FDA in the coming weeks and months, and still expect that a decision on the initial clearance of the Unyvero platform and LRT Application Cartridge could be issued in the second half of this year,” added Dr. Oliver Schacht, CEO of Curetis.
Disclaimer
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com – www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth@theruthgroup.com
Tel. +1 646 536 7012